Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Salix Pharmaceuticals Ltd -- Ignore unavailable to you. Want to Upgrade?

To: VIXandMore who wrote (4)	5/19/2004 12:28:38 PM
From: VIXandMore	Respond to of 5

Salix Pharmaceuticals Reports on Digestive Disease Week Activities RALEIGH, N.C.--(BUSINESS WIRE)--May 19, 2004--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP - News) today reported on several Company-related events that took place at Digestive Disease Week (DDW) earlier this week. DDW 2004 provided a venue for over 18,000 gastroenterologists and related health care providers to gain information on the latest advances in gastrointestinal research, medicine and technology. RIFAXIMIN AS A PROPHYLAXIS FOR TRAVELERS' DIARRHEA Dr. Herbert L. DuPont, Chief of Internal Medicine Service, St. Luke's Episcopal Hospital, Houston; Director, Center for Infectious Diseases, University of Texas, Houston School of Public Health; and Vice-Chairman, Department of Medicine, Baylor College of Medicine reported findings of a study investigating the use of rifaximin as a prophylaxis for travelers' diarrhea. The efficacy and tolerability of rifaximin as a prophylaxis for travelers' diarrhea was assessed in 220 U.S. adults in a randomized, double-blind placebo-controlled study. Subjects received rifaximin 200 mg either once, twice or three times daily or placebo three times daily for two weeks. Subjects were followed daily for three weeks for the occurrence of diarrhea, mild diarrhea or severe diarrhea. Subjects also were followed for five weeks for drug related side effects. Over the two-week treatment period 85 percent of the rifaximin-treated subjects compared with 49 percent of the placebo-treated subjects remained free of diarrhea. Additionally, rifaximin also prevented the occurrence of milder forms of diarrhea and prevented the occurrence of moderate and severe abdominal pain and cramps and excessive gas-related symptoms. The incidence of adverse events was comparable between each rifaximin group and placebo. CHEMOPREVENTION OF COLONIC POLYPS BY BALSALAZIDE Mesalamine previously has been reported in retrospective studies to reduce the risk of colitis-related neoplasia, and balsalazide (COLAZAL®), a prodrug of mesalamine, has been shown to prevent the growth of intestinal tumors in animals. Jonathan Terdiman of the San Francisco Veterans' Administration Medical Center and University of California San Francisco reported results of a prospective, randomized, double-blind placebo-controlled study conducted to examine the effect of balsalazide on the size and number of colorectal polyps in situ in humans. In this study, 86 patients with colonic polyps were treated with balsalazide (3 gm daily) or placebo for six months. Though the change in size and number of adenomas did not significantly differ between treatment groups, a trend was seen toward reduced total adenoma volume in those receiving balsalazide, suggesting that the rate of tubular adenoma growth may be slowed by balsalazide treatment. In addition, the slowing of adenoma growth was enhanced by concomitant aspirin use. Additional studies of different design and larger size are required to further investigate the chemopreventive effects of this agent. MEDICAL CROSSFIRE: DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL DISORDERS Approximately 500 gastroenterologists and other health care professionals attended a continuing medical education initiative - "Medical Crossfire: Diagnosis and Management of Gastrointestinal Disorders"- supported by an unrestricted educational grant from Salix. A panel of nationally recognized key opinion leaders comprised of Asher Kornbluth, M.D., Gary R. Lichtenstein, M.D., Mark Pimentel, M.D., Daniel H. Present, M.D., Ellen J. Scherl, M.D. and Steven R. Peiken, M.D. addressed current issues and challenges associated with the diagnosis and management of gastrointestinal disorders.